![Biology / Antibody-drug conjugate / Milatuzumab / Targeted therapy / Brentuximab vedotin / Yttrium (90Y) clivatuzumab tetraxetan / Hydrazone / Gemtuzumab ozogamicin / Monomethyl auristatin E / Monoclonal antibodies / Medicine / Pharmacology Biology / Antibody-drug conjugate / Milatuzumab / Targeted therapy / Brentuximab vedotin / Yttrium (90Y) clivatuzumab tetraxetan / Hydrazone / Gemtuzumab ozogamicin / Monomethyl auristatin E / Monoclonal antibodies / Medicine / Pharmacology](https://www.pdfsearch.io/img/255c9c4c49858992f80145684fe7eedb.jpg)
| Document Date: 2013-10-18 09:49:14 Open Document File Size: 1,27 MBShare Result on Facebook
Company Pfizer / IgG / ADC / Immunomedics / Seattle Genetics / Wyeth / ImmunoGen / Genentech / / Country United States / / Currency USD / / Event FDA Phase / Product Issues / Product Recall / / Facility ADC pipeline / pipeline ADCs / / IndustryTerm cancer therapy / cancer treatment / linker technologies / antibody coupling / chemical structure / alcohol chemical / / MedicalCondition tumor / Cancer / tumors / metastatic breast cancer / anaplastic large cell lymphoma / relapsed Hodgkin lymphoma / acute myeloid leukemia / / MedicalTreatment cancer therapy / / Organization FDA / Securities and Exchange Commission / / Person Cynthia L. Sullivan / / Position Private / President & CEO / / Product ADCs / Mylotarg / drug / SN-38 / polyethylene glycol / Kadcyla / / Technology linker technologies / treating cancer / /
SocialTag |